Injectables
6
Jul
PRESS RELEASE – Genoskin launches the ISR platform®
Genoskin announces the launch of the ISR platform®, a new pre-clinical toolbox designed to study injection site reactions (ISR) in humans ahead of clinical trials.
25
Oct
Genoskin granted new patent on subcutaneous injection model
Genoskin granted a new patent on ex vivo subcutaneous injection model The French National Institute for Intellectual Property (INPI) granted Genoskin's latest patent on its unique ex vivo subcutaneous injection model, HypoSkin®. A boom in the subcutaneous biologics market Today, subcutaneous injection is one of the most common methods to deliver a drug into the human body. Its use has increased significantlyRead more
27
Aug
[ESDR2019] Genoskin and Sanofi present Hypo-InflammaSkin®
[ESDR2019] Genoskin partners with Sanofi to present Hypo-InflammaSkin® Genoskin’s team of skin experts will be presenting its latest work at the 49th ESDR Annual Meeting from September 18 to September 21 in Bordeaux, France. To discover our latest research and innovations, meet our Project Manager and Team leader Claire Jardet, Ph.D. on Thursday 19th at 7 pm and Friday 20th atRead more
Ex vivo human skin platforms for better non-clinical decisions. Labs in France and the USA, serving 500+ customers worldwide.